Evidence map›Paper›PMID 39865537›Full record

ArticleFEBS open bio2025

Real-world genomic landscape of colon and rectal cancer.

Markus Schulze, XiaoZhe Wang, Jawad Hamad, Julia C F Quintanilha, Lincoln W Pasquina, Julia F Hopkins, Juergen Scheuenpflug, Zheng Feng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Markus SchulzeClinical Measurement Sciences, Global Research & Development, Merck KGaA, Darmstadt, Germany.
XiaoZhe WangClinical Measurement Sciences, Global Research & Development, EMD Serono, Billerica, MA, USA.
Jawad HamadMedical Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
Julia C F QuintanilhaFoundation Medicine Inc, Cambridge, MA, USA.ORCID https://orcid.org/0000-0001-6908-4474
Lincoln W PasquinaFoundation Medicine Inc, Cambridge, MA, USA.ORCID https://orcid.org/0009-0009-5461-9777
Julia F HopkinsFoundation Medicine Inc, Cambridge, MA, USA.
Juergen ScheuenpflugClinical Measurement Sciences, Global Research & Development, Merck KGaA, Darmstadt, Germany.
Zheng FengClinical Measurement Sciences, Global Research & Development, EMD Serono, Billerica, MA, USA.ORCID https://orcid.org/0000-0003-3858-2205

Funding

Merck Healthcare KGaA
6 · The paper itself

Abstract

MAPK signaling activation is an important driver event in colorectal cancer (CRC) tumorigenesis that informs therapy selection, but detection by liquid biopsy can be challenging. We analyze real-world comprehensive genomic profiling (CGP) data to explore the landscape of alterations in BRAF or RAS in CRC patients (N = 51 982) and co-occurrence with other biomarkers. A pathogenic RAS or BRAF alteration was found in 63.2% and 57.9% of colon and rectal cancer samples, respectively. In a subset of 140 patients with both tissue- and liquid-based CGP, the sensitivity of liquid for results found by tissue was 100% when ctDNA tumor fraction was at least 1%, illustrating the utility of tissue and liquid biopsy in detecting driver alterations in CRC.

Indexed as

Colonic NeoplasmsRectal NeoplasmsBiomarkers, TumorCirculating Tumor DNAFemaleGenomicsHumansLiquid BiopsyMaleMutationProto-Oncogene Proteins B-rafBiomarkers, TumorBRAF protein, humanCirculating Tumor DNAProto-Oncogene Proteins B-rafBRAFcolorectal cancerRASreal‐world data

Identifiers

PMID39865537
PMCPMC11961397

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.